There must be measurable disease at study entry\r\n* Note: a measurable node must have an LDi (longest diameter) greater than 1.5 cm; a measurable extranodal lesion should have an LDi greater than 1.0 cm; all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters)
Subjects must have measurable or evaluable disease:\r\n* Evaluable disease must be evidenced by computed tomography (CT) or positron emission tomography (PET) scans (abnormal PET scans may be used as long as the CT portion is of diagnostic quality)\r\n* Subject must have at least one objective measurable disease parameter:\r\n** Measurable disease on cross sectional imaging that is >= 2 cm in the longest diameter and measurable in 2 perpendicular dimensions\r\n** Splenomegaly > 13 cm in cranio-caudal dimension as measured by CT
Measurable disease sites on CT scan (>1.5 cm in longest dimension)
Measurable disease as defined by IWG for PTCL, i.e., at least 1 measurable disease lesion > 1.5 cm in at least one dimension by 18FDG-PET-CT, MRI, or diagnostic CT
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria that is:\r\n* A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI) and/or\r\n* A malignant lymph node is considered measurable if its short axis is > 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm)\r\n* Note: tumor lesions in a previously irradiated area are not considered measurable disease; disease that is measurable by physical examination only is not eligible
Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ? 1 lesion that measures > 1.5 cm in the longest dimension and ? 1.0 cm in the longest perpendicular dimension as assessed by computed tomography or magnetic resonance imaging.
Radiographic evidence of measurable disease tumor lesion (? 1cm in greatest dimension) or nodal disease (>1.5cm in greatest dimension)
Subject has measurable disease on cross-sectional imaging by computed tomography (CT) with at least one (post-biopsy) measurable lesion ? 2.0 cm in its longest dimension.
Radiographically measurable disease with a demarcated nodal lesion at least 1.5 cm in its largest dimension or a target extranodal lesion at least 1.0 cm in its largest dimension
For diseases other than Waldenstrom's macroglobulinemia (WM), presence of radiographically measurable presence of ? 1 lesion that measures ? 2.0 cm in the longest dimension (LD) and ? 1.0 cm in the longest perpendicular dimension (LPD)
Measurable disease by tumor imaging with at least one lesion >= 1.5 cm in at least one dimension
Measurable disease that has not been previously irradiated on computed tomography (CT) scans of at least 2 cm, OR if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; imaging must be completed no greater than 6 weeks prior to study enrollment
Participants must have measurable disease, defined as lymphocytosis >= 5,000/ul, or at least one palpable or CT measurable lesion > approximately 1.5 cm, or bone marrow involvement > approximately 30%
Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ?1 non-biopsied, non-irradiated lesion that measures ?2.0 cm in the longest dimension [LD] and ?1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]).
Have measurable disease (1.5 cm or greater in the longest diameter of nodal or extranodal disease)
Measurable Disease\r\n* Patients must have measurable disease per RECIST 1.1 by computer tomography (CT) scan or magnetic resonance imaging (MRI)\r\n* Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes); non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
Measurable disease that can be accurately measured in at least one dimension as >= 2.0 cm with computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) techniques; extranodal disease that is measurable by fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) imaging only will also be allowed; note that if an excisional biopsy was performed that removed the sole site of measurable disease, the patient will not be eligible for leukapheresis and generation of CAR T cell product
Measurable disease: for WM presence of monoclonal IgM immunoglobulin concentration on serum electrophoresis, with lymphoplasmacytic marrow infiltrate; for MZL: measurable nodal disease measuring at least 1.5 cm in longest dimension, or splenomegaly
Have measurable disease (>= 1.5 cm in the longest diameter for nodal or extranodal disease)
All patients should have measurable disease; measurable disease is defined as a lymph node or tumor mass that is >= 1.5 cm in at least one dimension by computed tomography (CT) or the CT portion of the PET/CT
Measurable disease: subjects must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography (spiral CT) or magnetic resonance imaging (MRI)
At least one non-nodal lesion considered measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (that is, a lesion whose longest diameter can be accurately measured as >= 1.0 cm with computed tomography [CT] scan, CT component of a positron emission tomography [PET]/CT, or magnetic resonance imaging [MRI]) or at least one malignant lymph node is considered measurable by RECIST criteria (that is, its short axis is >= 1.5 cm when assessed by CT scan)\r\n* NOTE: tumor lesions in a previously irradiated area are not considered measurable disease
For diseases other than CLL, LPL, and HCL, presence of radiographically measurable lymphadenopathy or extra-nodal lymphoid malignancy (defined as the presence of >= 1 lesion that measures >= 2.0 cm in the longest dimension [LD] and >= 1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]); for LPL, measureable disease will be defined as serum monoclonal IgM > 0.5 g/dL or meeting at least 1 of the recommendations from the Second International Workshop on LPL for requiring treatment
Patients should have measurable metastatic disease in the liver, defined (for the purpose of this study) as at least 1 measurable lesion more than 2 cm in size and readily accessible to ultrasound (US) or computed tomography (CT)-guided biopsy
Radiographically measurable disease by computed tomography (CT) scan, defined as at least one node > 1.5 cm in size or assessable disease
For subjects with DLBCL, FL, MCL, HL, or CLL/SLL: presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ?1 lesion that measures ?2.0 cm in the longest dimension [LD] and ?1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT]).
Disease that is measurable where:\r\n* A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)\r\n* A malignant lymph node is considered measurable if its short axis is >= 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; Note: disease that is measurable by physical examination only is not eligible
Measurable disease, defined as >= 1.5 cm on imaging assessment
Measurable disease as defined by at least one tumor that is measurable in two dimensions on CT or magnetic resonance imaging (MRI) scan (minimum size 1.0 cm for at least one lesion)
Measurable disease (at least 1 lesion >= 1.5 cm in diameter) as detected by PET/CT
Patients must have measurable disease defined by at least one of the following criteria:\r\n* Lesions greater than 1.5 cm that can be accurately measured in two dimensions by computed tomography (CT) (preferred), or magnetic resonance imaging (MRI), and are not included in any prior field of radiation given to treat B-NHL\r\n* In patients with CLL, circulating lymphocytes >= 5,000 / mm^3\r\n* In patients with WM/LPL, measurable serum monoclonal immunoglobulin M (IgM)
Patients must have primary tumor =< 10 cm as defined by computed tomography (CT) largest axial dimension
Patients must have measurable disease defined as lesions greater than 1.5 cm that can be accurately measured in two dimensions by CT (preferred), or MRI
Must have measurable disease (e.g., a tumor mass > 1 cm)
Measurable or assessable disease is required; measurable tumor size (at least one node measuring 2.25 cm^2 in bidimensional measurement) per computed tomography (CT) scan, other radiological study, and/or physical exam
In cases of SLL, subjects must have at least one bidimensionally measurable lesion; one of the measurements must be >= 1.5 cm in one dimension
History of uveal melanoma and documented metastatic disease with at least one measurable lesion is required; which is >= 1 cm x 1 cm (on spiral computed tomography [CT] or equivalent)
Measurable disease:\r\n* For nodal or extranodal disease (lymphoma or breast): must have at least 2 lesions that are >= 20 mm (2.0 cm) in the longest diameter by physical exam and/or on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography PET-computed tomography (CT), that are amenable to intralesional injections as determined by interventional radiology (including tumors that can be safely accessed using imaging guidance and treated with minimal risk to adjacent structures)\r\n* For cutaneous lesions (lymphoma or breast): at least two visible, non-infected skin lesions that are greater than 1 cm and are amenable to intralesional injection
Ann-Arbor Stage 2 (non-contiguous), 3, or 4 disease per Lugano Classification Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ? 1 lesion that measures ? 1.5 cm in the longest dimension (LD) and ? 1.0 cm in the longest perpendicular dimension (LPD) as assessed by positron emission tomography-computed tomography (PET-CT), computed tomography (CT) or magnetic resonance imaging (MRI)
Measurable disease with a lymph node or tumor mass >1.5 cm in at least one dimension as assessed by computed tomography (CT)
107 Radiographically measurable disease with a clearly demarcated nodal lesion at least 1.5 cm in its largest dimension or a target extranodal lesion at least 1.0 cm in its largest dimension. In the dose exploration phase in case disease is not radiographically measurable PET positivity (ie, Deauville ?4) instead is acceptable.
Measurable disease defined as:\r\n* Computed tomography (CT)/magnetic resonance imaging (MRI)/ or positron emission tomography (PET) scan, with at least one nodal site of disease which is 1.5 cm in longest dimension, and/or spleen > 13 cm in vertical length, and/or diffuse enlargement of liver with or without focal nodules (Lugano 2014); extra nodal sites with biopsy proven abnormal lesions are allowed including skin\r\n* Patients with only bone marrow involvement will be acceptable
Measurable disease by CT or MRI, but with no single lesion measuring more than 10.0 cm
For diseases other than LPL and CLL, presence of radiographically measurable lymphadenopathy or extra-nodal lymphoid malignancy (defined as the presence of >= 1 lesion that measures >= 2.0 cm in the longest dimension [LD] and >= 1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT] or magnetic resonance imaging [MRI]); for LPL, measurable disease will be defined as serum monoclonal IgM > 0.5 g/dL or meeting at least 1 of the recommendations from the Second International Workshop on LPL for requiring treatment
Measurable disease is defined as at least one lesion that can be accurately measured with the longest diameter as >= 1.0 cm by computed tomography (CT) scan or >= 1.0 cm with calipers by clinical examination; the exceptions to these criteria are pathologic lymph nodes, which must be >= 1.5 cm in the short axis when assessed by CT scans with slice thickness =< 0.5 cm
Appropriate stage for study entry based on the following diagnostic workup:\r\n* All patients must have computed tomography (CT) scan chest/abdomen/pelvis with multiphasic liver CT scan prior to registration; if CT contrast is contraindicated, CT chest without contrast and magnetic resonance imaging (MRI) of abdomen is permitted\r\n* Participants must have measurable disease at study entry, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 2 cm with conventional techniques or as > 1 cm with spiral CT scan\r\n* Patient must have 3 or fewer single or multinodular tumors; for patients with a single lesion, lesion must be 15 cm or less in greatest dimension; for patients with two lesions, no lesion may be greater than 10 cm in greatest dimension; for patients with three lesions, no lesion may be greater than 6 cm in greatest dimension; portal vein involvement or thrombosis combined with a single lesion that is >= 4 cm and =< 15 cm in greatest dimension is allowed
Gynecologic cancer cohort only: measureable disease, defined as at least one lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with CT scan or MRI scan; or CT component of a PET/CT; NOTE: Disease that is measurable by physical examination only is not eligible; EXCEPTION: Patients with ovarian, fallopian, or peritoneal cancer without measurable disease are eligible if two pretreatment CA125 values (documented on two occasions taken at least one week apart) are at least twice the upper limit of normal or twice the nadir value if pretreatment CA125 values never normalized.
Measurable disease, defined as one or more of the following:\r\n* Lymphocytosis >= 5000 in peripheral blood\r\n* Measurable lymph nodes > 1.5 cm on palpation and/or computed tomography (CT) scan\r\n* Organomegaly by physical exam and/or CT scan
Measurable disease as defined by the Cheson Response Criteria for Malignant Lymphoma with at least one lesion >= 1.0 cm in longest diameter by computed tomography (CT) scan
Measurable disease\r\n* Mammographic extent of calcifications must be accurately measurable in at least one dimension with each lesion >= 1 cm and =< 7 cm\r\n* DCIS must be visible on MRI based on central review\r\n* Patients with palpable DCIS or adenopathy are not eligible to participate\r\n* Patients with multifocal or bilateral disease are eligible
Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of a ?1.5 cm lesion, as measured in the longest dimension by computed tomography [CT] scan).
Must have ? 1 measurable lesion (?2 cm in longest dimension) or ? 1 measurable extranodal lesion (?1 cm in longest dimension) on computed tomography (CT) scan or magnetic resonance imaging (MRI).
Measurable disease on cross section imaging by CT (computed tomography) that is at least 1.5 cm in the longest diameter and measurable in two perpendicular dimensions as defined by IWG (International Working Group) response criteria for NHL (non-Hodgkin Lymphoma).
Subject with lymphoma who has measurable disease (? 2.0 cm in its longest dimension by computed tomography) or chronic lymphocytic leukemia in need of treatment.
At least 1 measurable (? 2 cm in longest dimension) lesion on CT scan or magnetic resonance imaging (MRI).
Measurable disease on cross section imaging that is at least 1.5 cm in the longest diameter and measurable in two perpendicular dimensions
Have measurable disease (>= 1.5 cm in the longest diameter for nodal or extranodal disease)
Measurable disease sites on CT scan (>1.5 cm in longest dimension)
Measurable disease (at least one lesion that is 1.5 cm in the longest diameter on cross?sectional imaging and measurable in 2 perpendicular dimensions per computed tomography [CT]) for non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) subjects; for myeloma patients measurable disease is defined as presence of more than 5% plasma cells in the bone marrow aspiration and/or presence of monoclonal gammopathy in serum protein electrophoresis (SPEP) and immunofixation
Participants must have measurable disease (lymphocytosis > 5,000/ul, or palpable or CT measurable lymphadenopathy > 1.5 cm, or bone marrow involvement > 30%)
Measurable disease with a lymph node or tumor mass > 1.5 cm in at least one dimension as assessed by computed tomography (CT)
Measurable disease with a lymph node or tumor mass ?1.5 cm in at least one dimension by CT, PET/CT or MRI.
Patients must have measurable disease per RECIST 1.1 by computed tomography (CT) scan or magnetic resonance imaging (MRI); lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes); index lesions for the purpose of RECIST 1.1 measurements will not be selected from within the radiation therapy treatment field; however, if there is evidence of disease progression within the radiation treatment field, measurement of the progressing lesions will be documented
Measurable disease as assessed by 2 dimensional measurement by computed tomography (CT) (> 2 cm or 1.5 cm if 0.5 cm slices are used, as in spiral CT scan)
Patient has measurable disease as defined by a tumor mass > 1.5 cm in one dimension.
Measurable disease defined as: \r\n* At least one non-nodal lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with spiral computed tomography (CT) scan, >= 2 cm with CT component of a positron emission tomography (PET)/CT or magnetic resonance imaging (MRI); and/or\r\n* A lymph node whose short axis must be > 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; disease that is measurable by physical examination only is not eligible
Measurable disease as assessed by 2 dimensional measurements by computed tomography (CT) (>= 1.5 cm)
Measurable disease defined by at least 1 lesion >= 1 cm
Measurable disease with a lymph node or tumor mass >1.5 cm in at least one dimension as assessed by computed tomography (CT)
Must have measurable disease (e.g., a tumor mass > 1 cm)
Measurable disease of at least 1.5 cm
Must have a documented diagnosis of CLL/ SLL requiring treatment (per IWCLL guidelines). In addition: a. Presence of at least one clinically measurable lesion: i. nodal lesion that measures ? 1.5 cm in longest dimension (LD) and ? 1.0 cm in longest perpendicular dimension (LPD), or ii. spleen that measures ? 14 cm in longest vertical dimension (LVD) with a minimum of 2 cm enlargement, or iii. liver that measures ? 20 cm in LVD with a minimum of 2 cm enlargement, or iv. peripheral blood B lymphocyte count > 5000/uL.
Patients must have measurable disease to be treated with proton radiation (minimum tumor dimension at least 10 mm on CT imaging)
At least one measurable lesion ? 2 cm in longest diameter by CT and/or MRI scan
At least one measurable lesion that is > 1.5 cm in at least one dimension
?1 measurable lesion site on CT scan (>1.5 cm in longest dimension). Lesions in anatomical locations (such as extremities or soft tissue lesions) that are not well visualized by CT may be measured by MRI instead. (Subjects with spleen-only disease are considered as not having measurable disease.)
Measurable disease of at least 1.5 cm
Bidimensionally measurable disease with at least 1 lesion >= 2.0 cm in a single dimension
At least one lesion by CT or MRI ? 2 cm
Participants in the Kinetic Studies Arm cannot have non-measurable disease (< 1 cm) by CT
Measurable disease on MRI defined as tumor measuring at least 1 cm in two perpendicular dimensions
Measurable disease (>= 1.5 cm) as assessed by 2 dimensional measurement by computed tomography (CT)
Measurable disease (at least one lesion on radiographic or exam assessment measuring >= 2 cm in longest axis)
For iNHL: measurable nodal disease, defined as the presence of >= 1 nodal lesion that measures >= 2 cm in a single dimension as assessed by computed tomography (CT) or magnetic resonance imaging (MRI)
Criteria 4, Participants have measurable disease which is equal to one or more metastatic liver lesions that can be accurately and serially measured that are greater than or equal to 1 cm dimension and for which the longest diameter is greater or equal to 1 cm as measured by CT (Computed Tomography) scan or magnetic resonance imaging. The metastatic liver lesion(s) must not be in an area that received prior localized therapies.
Total sum of maximum diameters of each definite parenchymal hepatocellular carcinomas within the liver or maximum diameter of a single conglomerate HCC > 20 cm
Group A will be further split into two subsets, which are mutually exclusive, for statistical purposes\r\n* Group A1:\r\n** > 6 months and < 12 months of age with an adrenal primary tumor < 5 cm in greatest diameter OR\r\n** Patients less than 6 months of age with an adrenal primary tumor > 3.1 and < 5 cm in greatest diameter OR\r\n** < 12 months of age with a non-adrenal primary site < 5 cm in greatest diameter\r\n* Group A2: =< 6 months of age with an adrenal primary site and tumor =< 3.1 cm in greatest diameter.
Postoperative tumor plus surgical bed size exceeds 5 cm in maximum diameter
Maximum diameter of individual metastasis in any dimension =< 5 cm
SBRT target size > 8 cm in maximum diameter (or > 100 cc in volume)
Lesion larger than 3 cm in diameter
At least 1 cutaneous or subcutaneous Injectable Lesion with longest diameter at least 5 mm.
Patients must have measurable disease (defined as >= 1.5 cm in diameter)
Subjects must have measurable disease of at least 1.5 cm in diameter
The contrast-enhancing intraparenchymal brain metastases(s) must be well circumscribed and must have a maximum diameter of =< 3.0 cm in any direction on the enhanced scan
Participants with a maximum tumor diameter exceeding 5 cm (if not resected)
Non-nodal lesion that measures ?1.0 cm in the longest diameter;
Recurrent lesion must be >= 1.0 cm in diameter as determined by MRI
Participants with a maximum tumor diameter exceeding 5 cm (if not resected)
longest tumor diameter < 3 cm
TREATMENT EXCLUSION: Bulky disease (defined as a 10 cm mass or mediastinal disease with a transverse diameter exceeding 33% of the transthoracic diameter)
Participants must have at least 1 of the following: 1 site of measurable disease greater than (>) 1 centimeter (cm) in the longest diameter and >1 cm in the shortest diameter by radiological imaging; bone marrow involvement; cerebrospinal fluid with blasts present
One or more high-risk features identified:\r\n* Tumor diameter >= 1 cm (phase I component) or >= 2 cm (phase II component)\r\n* Tumor standardized uptake value maximum (SUVmax) >= 6.2\r\n* Moderately, poorly differentiated or undifferentiated histology
SBRT or hypofractionated IMRT target size > 10 cm in maximum diameter (or greater than 100 cc in volume)
EXCLUSION CRITERIA FOR STRATUM C: Patients with bulky tumor on imaging are ineligible; treating physicians are encouraged to contact the study chair to request a rapid central imaging review to confirm fulfilment of these eligibility criteria, if they have concerns; bulky tumor is defined as:\r\n* Tumor with any evidence of uncal herniation or midline shift\r\n* Tumor with diameter of > 5 cm in one dimension on T2/FLAIR\r\n* Tumor that in the opinion of the site investigator, shows significant mass effect\r\n* Metastatic disease: Patients with =< 5 separate foci of metastatic disease not causing mass effect on adjacent parenchyma and each measuring less than 0.5 cm in maximum diameter will be eligible for this arm of the study; patients with diffuse linear leptomeningeal spread are not eligible for this arm of the study\r\n* Multi-focal disease: Patients with multi-focal parenchymal disease will be eligible for stratum C if the sum of the product of the maximum perpendicular diameters of all measurable non-contiguous lesions is less than 16 cm^2; in such cases, a minimum of 2 and a maximum of 5 “target” non-contiguous lesions will be selected; the lower size limit of the target lesion(s) should be at least twice the thickness of the slices showing the tumor to decrease the partial volume effect (e.g., 8 mm lesion for a 4 mm slice)
At least one endoscopically measurable tumor 6 - 10mm in diameter
Single measurable lesion < 4 cm in longest diameter
Clinically or radiologically measureable disease in the breast after diagnostic biopsy, defined as longest diameter greater than or equal to 25 mm (2.5cm)
Maximal tumor diameter of 6.6 cm or less; patients with multifocal tumors are allowed if the sum of the maximal tumor diameters does not exceed 6.6 cm; note, the maximal tumor diameter for the first 3 subjects enrolled will be 5 cm
No more than 3 lesions may be treated; the maximum sum of the diameter(s) of the lesion(s) must be =< 6 cm
Patients with a measurable disease, defined by a node or mass with the longest diameter >= 1.5 cm.
Tumor diameter in the plane perpendicular to LITT trajectory must be =< 3.5 cm in diameter
Patients must be a candidate for intralesional therapy\r\n* At least 1 injectable cutaneous, subcutaneous, or nodal melanoma lesion >= 10 mm in longest diameter OR\r\n* Multiple injectable melanoma lesions which in aggregate have a longest diameter of >= 10 mm\r\n* Must have no known bleeding diathesis or coagulopathy that would make intratumoral injection unsafe
Patients must have an indication for therapy per standard modified Groupe d’Etude des Lymphomes Folliculaires (GELF) criteria including:\r\n* Symptoms attributable to lymphoma, threatened end-organ function, cytopenia secondary to lymphoma, bulky disease (defined as: single mass > 7 cm in diameter, or 3 or more masses > 3 cm in diameter), splenomegaly, and steady progression over at least 6 months
Maximum volume of largest lesion =< 5 cm^3\r\n* This volume limit would be equivalent to a largest diameter of about 2.1 cm, assuming a perfect sphere
At least one measurable intracranial target lesion for which all of the following criteria are met: a) Previously untreated or progressive after previous local therapy b) Immediate local therapy clinically not indicated or patient is not a suitable candidate to receive immediate local therapy c) Largest diameter of >= 0.5 cm, but =< 3 cm as determined by contrast-enhanced MRI
Histologically or cytologically confirmed, primary or recurrent, head and neck squamous cell carcinoma, including variants; patients must have at least one measurable lesion in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (tumor diameter >= 1 cm; short-axis lymph node diameter >= 1.5 cm) OR by caliper measurement (tumor diameter >= 1 cm); any diagnostic pretreatment biopsy sample is acceptable including fine needle aspiration (FNA)
Any tumor mass greater than 10 cm in longest diameter
For part 1, subject will have ? 1 and ? 5 tumors (prior to TURBT), none of which exceeds 3.0 cm in diameter; for part 2, patient will have ? 2 and ? 5 tumors (prior to TURBT), none of which exceeds 3.0 cm in diameter (resection loop ~1 cm).
Histologically/cytologically confirmed locally advanced pancreatic adenocarcinoma; at least one lesion with a diameter of at least 1.5 cm but no more than 6 cm as documented via CT scan (within 6 weeks of Screening);
Patients with lymphoma masses 10.0 cm or larger in longest diameter will not be eligible
Subjects must have measurable plexiform neurofibroma(s) amenable to volumetric MRI analysis; the target lesion must be seen on at least 3 consecutive MRI slices and the field of view must contain the entire tumor of interest; tumors must be at least 3 milliliter (mL) in volume (most plexiform neurofibromas [PN] 3 cm in longest diameter will meet this criteria); if the tumor is < 3 cm in longest diameter, the patient may still be eligible; central review of the MRI of the target plexiform is required prior to enrollment to ensure that the tumor is measurable and amenable to volumetric analysis
FOR TCL ONLY: Measurable disease by CT or magnetic resonance imaging (MRI): must have at least one lesion that has a single diameter of > 2 cm or tumor cells in the blood > 5 x10^9/L; NOTE: skin lesions can be used if the area is > 2 cm in at least one diameter and photographed with a ruler and the images are available in the medical record
MULTIPLE MYELOMA ONLYMultiple : >= 15% plasmas cells or plasmacytoma > 5 cm in largest diameter
Largest lesion =< 4 cm diameter
Less than 3 nodal sites, each with diameter >3 cm
Each brain lesion must be less than or equal to 5 cm in diameter and not an optimal surgical candidate
Brain lesion(s) greater than 5 cm in diameter
Well-circumscribed, measurable intraparenchymal brain lesion(s) with maximum tumor diameter =< 3.0 cm; if multiple lesions are present, the other(s) must not exceed 3.0 cm in maximum diameter; at least one lesion must be >= 0.5 cm in maximum diameter to be considered measurable disease
The maximum diameter of any lesion must be less than 4.0 cm
Significant extrahepatic disease\r\n* Symptomatic extrahepatic disease (including primary tumor, if unresected)\r\n* Greater than 10 pulmonary nodules (each =< 20 mm in diameter) or combined diameter of all pulmonary nodules > 15 cm\r\n* Peritoneal carcinomatosis
A diagnostic contrast?enhanced MRI of the brain must be performed within 60 days prior to registration; the contrast?enhancing intraparenchymal brain tumor must be well circumscribed and must have a maximum diameter of =< 4.0 cm in any direction on the enhanced scan; if multiple lesions are present and one lesion is at the maximum diameter, the other(s) must not exceed 3.0 cm in maximum diameter
Participants must have stable or responding systemic disease to TKI (no evidence of progression) on the most recent staging studies; the required staging studies are: (1) a re-staging computed tomography (CT) scan of the chest +/- abdomen with intravenous (IV) contrast (unless medically contraindicated) within 2 months of study enrollment; and (2) in patients with known brain metastasis, or to investigate patients with new onset of neurologic symptoms that may suggest metastasis to the brain, brain magnetic resonance imaging (MRI) with gadolinium, or head CT scan with IV contrast will be required within 2 months of study enrollment; the complete extent of the current residual systemic disease must be deemed amenable to SBRT as per review of imaging studies by a radiation oncologist involved in this trial; this will be based on the following criteria:\r\n* Lung: 1-3 lesions (including the primary) of maximum size 5 cm in longest diameter; a minimum size 1 cm in the longest diameter is recommended; (patients with a malignant pleural effusion prior to the start of TKI therapy will be considered eligible for SBRT if there is complete radiographic resolution of the effusion while on systemic therapy)\r\n* Spine: bone lesions must be limited to the spine; a maximum of 2 spinal metastases will be considered for SBRT, with each site spanning 1-3 vertebral bodies; a minimum size of 1 cm in longest diameter is recommended; SBRT may target sclerotic lesions that persist following TKI therapy\r\n* Gastrointestinal (GI): 1-4 liver metastases of maximum size 5 cm in longest diameter and/or 1-2 adrenal metastases of maximum 4 cm size in longest diameter; a minimum size of 1 cm in longest diameter is recommended\r\n* In addition:\r\n* Central nervous system (CNS): 1-4 brain metastases of maximum size 3cm in longest diameter; however, these should be treated with standard-of-care stereotactic radiosurgery (SRS) and will not be defined as target lesions for purposes of this protocol; there is no minimum size requirement for treatment of brain lesions but small foci of potential disease (1-4 mm size) detected on high-resolution MRI may not be clinically relevant and do not count towards the maximum number of 4 brain metastases as per the treating radiation oncologist’s discretion and in line with institutional practice\r\n* A maximum number of 5 target lesions outside the brain, excluding the lung primary, is recommended to ensure that enrollment is limited to patients with low-burden disease and that treatments can be delivered within the specified time frame; this is not an absolute requirement as situations may exist when more than 5 metastatic targets are appropriate in the treating radiation oncologist’s clinical judgment, for example when nearby lesions can be included in a single treatment field
Diagnosed with a single HCC lesion ? 3.0 cm but ? 7.0 cm in maximum diameter based on diagnosis at screening.
Recurrent tumor must be a solid, single, supratentorial, contrast-enhancing HGG which have a tumor diameter no larger than 4 cm or volume of 34 cm^3
Maximum tumor size ?1.5 cm in its greatest diameter
Brain MRI with contrast demonstrates an enhancing tumor =< 8 cm in largest diameter within 30 days prior to registration
Any significant CNS hemorrhage defined as > 1 cm diameter of blood seen on the pre-registration brain MRI with contrast scan; if > 1 cm of acute blood is detected, the patient will be ineligible for this trial
Patient must have > 1 lesion; combined diameter of the lesions must be of size > 1.5 cm
Lesions to be treated under this protocol must be > 2 cm, but =< 4.0 cm in diameter
Prior wide excision with diameter of the excision > 3 cm
All patients must be eligible to have all lesions treated with SRS (i.e. maximum diameter of largest lesion < 3.5 cm) as determined by the radiation oncologist
Disease bulk defined as any lymph node mass with transverse maximal diameter > 7.0 cm OR coronal maximal diameter > 7.0 cm on CT imaging
At least one brain metastasis (index tumor) must be within 2-6 cm in maximum diameter and deemed appropriate for surgical resection by the treating neurosurgeon
The Target Lesion must have measurable disease, defined as a unidimensionally measurable lesion ? 1.0 cm in longest diameter by helical CT; the maximum diameter of the Target Lesion shall be ? 4.9 cm.
lesion(s) diameter is ? 2 cm
Targeted tumors (most painful) size up to 8 cm in diameter
Targeted (most painful) tumors size > 8 cm in diameter
Patients must have measurable FDG-avid disease defined by standard criteria (Lugano 2014) and a minimum of 1.0 cm in diameter
No single lesion can be larger than 3 cm in maximal diameter; there may not be midline shift exceeding 5 mm or hydrocephalus
Maximum diameter of enhancing tumor (target lesion) should be =< 4 cm
Has recurrent or persistent tumor (enhancing area) greater than 4 cm in maximum diameter
Each lesion must be less than or equal to 5 cm in maximal diameter and multiple lesions must be less than or equal to 18 cm for the sum of the diameters in 3 dimensions; Example: 3 lesions each 2 + 2 + 2 cm have an aggregate diameter of 18 cm which is acceptable
The T stage must be Tis, T1, or T2; if T2, the tumor must be =< 3.0 cm in maximum diameter
T stage of T2 with the tumor > 3 cm in maximum diameter or a T stage >= 3
Patients with up to 3 brain metastases (symptomatic and non-symptomatic) can be treated on this study; maximum diameter of each brain lesion should be =< 5 cm; maximum tumor volume =< 120 cc
Tumor diameter =< 7 cm
Bulky disease by CT, defined as any single mass > 10 cm in its greatest diameter
Cohort A (asymptomatic patients): At least 1 measurable brain metastasis ? 0.5 cm in and ? 3 cm in longest diameter that has not been previously irradiated. No clinical requirement for local intervention (surgery, radiosurgery, corticosteroid therapy) or other systemic therapy Cohort B (symptomatic patients): Subjects with neurologic signs and symptoms related to metastatic brain lesions are eligibile. Subjects must have at least 1 measurable brain metastasis ? 0.5 cm in and ? 3 cm in longest diameter that has not been previously irradiated. No immediate requirement (within 3 weeks prior to first treatment) for local intervention (surgery, radiosurgery, corticosteroid therapy). Steroid use is permitted as defined in the protocol.
Measurable disease with at least one extranodal tumor mass >1.0 cm in the greatest transverse diameter (GTD) or in the case of malignant lymph nodes >1.5 cm in the GTD.
Prostate calcifications > 1 cm in largest diameter, on Baseline Ultrasound
Cysts > 1 cm in largest diameter, on Baseline MRI
Subject must have measurable disease and must be a candidate for intralesional therapy with at least one injectable cutaneous, subcutaneous, or nodal melanoma lesion (? 10 mm in longest diameter) or with multiple injectable lesions that in aggregate have a longest diameter of ? 10 mm.
Evidence of necrotic or > 1.5 cm in diameter pelvic (iliac/inguinal) nodes
at least one bidimensionally measurable, PET positive disease site (transverse diameter of ?1.5 cm and perpendicular diameter of ?1.0 cm at baseline)
Must be in need of therapy as evidenced by at least one of the following criteria: \r\n* Bulky disease defined as:\r\n** A nodal or extranodal (except spleen) mass > 7 cm in its greater diameter or,\r\n** At least 3 nodal or extranodal sites >= 3 cm in diameter\r\n* Presence of at least one B symptom:\r\n** Fever (> 38 C) not due to infectious etiology\r\n** Night sweats\r\n** Weight loss > 10% in the past 6 months\r\n* Fatigue due to lymphoma\r\n* Splenomegaly (> 13 cm)\r\n* Compression syndrome (ureteral, orbital, gastrointestinal)\r\n* Any of the following cytopenias due to lymphoma:\r\n** Hemoglobin =< 10 g/dL\r\n** Platelets =< 100 x 10^9/L\r\n** Absolute neutrophil count (ANC) < 1.5 x 10^9/L\r\n* Pleural or peritoneal effusion\r\n* Lactate dehydrogenase (LDH) > upper limit of normal (ULN) or beta-2 microglobulin > ULN
Subjects must be candidate for intralesional injection into cutaneous, subcutaneous or nodal tumors with or without image ultrasound guidance defined as one or more of the following at least 1 injectable lesion >= 5 mm in longest diameter, multiple injectable lesions that in aggregate have a longest diameter of >= 5 mm
Primary tumor diameter ?40 mm
Maximum diameter of enhancing tumor (target lesion) should be =< 3.5 cm
Has recurrent or persistent tumor (enhancing area) greater than 3.5 cm in maximum diameter
The lesion can be accurately measured in at least one dimension as greater than or equal to 1.0 cm (viable tumor for typical; and longest diameter for atypical), and
Meets Milan criteria: a single tumor that is < 5 cm or a maximum of 3 tumors with each tumor < 3 cm AND/OR meets UCSF criteria: a single tumor that is < 6.5 cm in diameter or 2 lesions < 4.5 cm with total tumor diameter < 8 cm AND/OR is outside of both Milan and UCSF criteria and is being evaluated for downstaging
Patient must have bi dimensionally measurable disease, per the proposed Response Assessment in NeuroOncology (RANO; Appendix C) (Wen et al., 2010), with measurement of >1 cm in one diameter and ?5 cm diameter in any plane on MRI performed within 2 weeks prior to randomization.
Patient will have ?4 tumors, none of which exceeds 3.5 cm in diameter.
Patients must have at least 3 distinct metastatic sites with at least one measurable lesion which is at least 1 cm or larger in largest diameter
Bulky disease - Lymph nodes or tumor mass (except spleen) >= 7cm LD (longest diameter)
Primary tumor greater than (>) 2 centimeters (cm) in diameter, or > 5 millimeters (mm) in diameter and node-positive
Measurable disease: subjects must have measurable plexiform neurofibroma(s) amenable to volumetric MRI analysis; for the purpose of this study, the target lesion must be seen on at least 3 consecutive MRI slices and the field of view must contain the entire tumor of interest; tumors must be at least 3 mL in volume (most PNs 3 cm in longest diameter will meet this criteria); if the tumor is < 3 cm in longest diameter, the subject may still be eligible; central review of the MRI of the target plexiform is required prior to enrollment to ensure that the tumor is measurable and amenable to volumetric analysis
Bulky celiac adenopathy (i.e., >= 2.5 cm in diameter)
Recurrent or persistent tumor greater than 6 cm in maximum diameter
Previously untreated stage I or II non-bulky Hodgkin lymphoma\r\n* No mediastinal mass > 0.33 maximum intrathoracic diameter on chest x-ray, if available; chest x-ray is not required\r\n* No adenopathy > 7.5 cm in its largest diameter
Bulky disease (defined as a mass measuring > 7.5 cm or one-third the maximal diameter of the thoracic cavity)
At least 1 measurable target brain lesion >0.5 cm and no larger than 3 cm in diameter and/or 2 measurable brain target lesions >0.3 cm
Combined diameter of all liver lesions must be =< 6 cm
Patients must have a mediastinal mass > 0.33 maximum intrathoracic diameter on standing posterior-anterior chest x-ray or mass measuring > 10 cm in its largest diameter
Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ? 1 lesion that measures > 1.5 cm in the longest transverse diameter and ? 1.0 cm in the longest perpendicular diameter.
(continued from no. 1) Those patients with stage III cancer in which the largest maximal diameter of any residual tumor implant at the completion of this initial surgery is no greater than 1 cm will be defined as optimal; all others will be defined as suboptimal.
The resection cavity must have a maximum diameter of less than or equal to 4 cm; this criteria will be determined by the study radiologist)
Additional unresected brain metastases (up to 2) must have a maximum diameter of less than or equal to 3 cm
Patients with suspected colorectal cancer with nodules in the lung or liver (1-2 cm in diameter) will be eligible for this study.
AP diameter of the prostate must be ?4.0cm;
Meets UCSF criteria: a single lesion less than or equal to 6.5 cm in diameter or 2-3 lesions less than or equal to 4.5 cm with total tumor diameter less than or equal to 8 cm.
Maximum diameter exceeding 12 cm (maximum diameter does not include satellite lesion)
At least one unidimensionally measurable tumor lesion >= 1 cm in longest diameter using spiral computed tomography (CT) (>= 2 cm in longest diameter by any other technique) that has not been radiated and is not located in a bone
MRI with a contrast-enhancing tumor of at least 1 cm (10 mm) in the longest diameter.
Diagnosis of BCC with at least 6 nodular lesions that measure 0.5 cm to 5 cm in diameter, located on the head and neck, trunk or extremities
Breast tumor ?1 centimeter (cm) in diameter, HR+, HER2-.
No lesion > 50 mm in longest diameter; and no more than 50 lesions
CT imaging in screening (based on local evaluation) showing 2 or more clearly demarcated lesions with a largest diameter > 1.5 cm, or 1 clearly demarcated lesion with a largest diameter > 2.0 cm.
Patients with 1 focus of HCC will be eligible if their tumor is 3.5 cm or less in greatest diameter; patients with 2 foci of HCC will be eligible if each lesion is 3.5 cm in diameter or less and the combined diameter of both lesions is 5 cm or less
Recurrent/metastatic radioiodine refractory disease that has progressed within the past 6 months with at least 1 lesion increasing by 0.5 cm in diameter or with increasing bone metastases
The contrast-enhancing intraparenchymal brain tumor must be well circumscribed and must have a maximum diameter of =< 4.0 cm in any direction on the enhanced scan; if multiple lesions are present and one lesion is at the maximum diameter, the other(s) must not exceed 3.0 cm in maximum diameter
1 to 10 brain metastases (mets) (no more than two lesions and/or cavities >= 3 cm in maximum diameter)
Maximum diameter of brain metastasis or resection cavity is 6 cm
Non-bulky disease defined as less than 10 cm in maximal diameter
At least one pulmonary metastasis ? 3.0 cm in maximum diameter resulting from distant primary cancers or at least one recurrence of primary lung cancer ? 3.0 cm in maximum diameter.
The clinical or radiologic primary tumor size is at least 1.5 cm diameter
Subject's tumor(s) must be < 3.0 cm in greatest diameter by pre-operative assessment
Documented history of advanced adenomas (>= 1 cm in maximal diameter, >= 3 in total number, villous morphology, or high?grade dysplasia) or colorectal cancer
The size of the target nodule, as measured at its greatest diameter, is between 1-3cm,
Patient with either a single focus or multiple foci (multi-isocentric planning) of disease in the thorax amenable to SBRT with at least one focus with at least 1.5 cm or larger in its largest diameter
Patients with measurable colorectal liver metastases on prior imaging, with at least one tumor greater than 2.0 cm in axial maximal diameter
An indeterminate pulmonary nodule (IPN) (7–30 mm diameter) on CT, or an indeterminate lung mass (> 30 mm diameter), without prior examinations that establish that the lesion has been stable for two or more years
Metastatic spinal lesions 1 cm or greater in diameter
Lesions of 5 cm or less in maximum diameter
Nodule to be biopsied is greater than 3.0 cm in maximum diameter;
Have measurable disease in their skin by direct visualization (visible lesion typically > 0.5 cm in maximal diameter); to perform a microscopic observation, the lesion will have to be visible by the naked eye, lined-up visually, and be able to interface with the microscope objective; a melanoma lesion that is smaller than 0.5 cm in diameter would present several obstacles to obtaining a reliable microscopic observation in the operating room; therefore, a visible lesion, at a minimum of 0.5 cm in diameter, is proposed for this study
FINAL ENROLLMENT BIOPSY PARAMETERS: no demonstrated cancer diameter > 1.2 cm
Patients with tumor size greater than 5 cm in diameter as measured at imaging (ultrasonography or MRI) before treatment
Maximal tumor diameter > 4 cm
PART B: Advanced solid tumor malignancy and the presence of at least one liver metastasis measuring > 1.5 cm in longest diameter in axial dimension on standard anatomic imaging
Patients should have at least one tumor deposit that is > 1.0 cm in diameter, and that is amenable to imaging
Non-nodal lesion that measures ?1.0 cm in the longest diameter ii.Participants with ICC:
Clinically or radiologically measurable disease in the breast after diagnostic biopsy, defined as longest diameter greater than or equal to 2.0 cm
Subject must be a candidate for intralesional injection, defined as one or more of the following: • at least 1 injectable lesion ? 10 mm in longest diameter • multiple injectable lesions that in aggregate have a longest diameter of ? 10 mm
At least one bi-dimensionally measurable lesion (greater than [>] 1.5 centimeters [cm] in its largest dimension by CT scan or magnetic resonance imaging [MRI])
At least one bi-dimensionally measurable lesion
Patients must have bi-dimensionally measurable disease (>= 1 cm) by CT imaging\r\n* NOTE: patients with marrow-only disease are eligible; response for these patients will be assessed by repeat bone marrow biopsy
Patients must have bi-dimensionally measurable disease (at least 1 cm); NOTE: patients with fully resected disease are eligible, and will be evaluable for all toxicity and efficacy endpoints except objective response
Women with an abnormal mammogram (BI-RADS final assessment category 3-probably benign, 4-suspicious, or 5-malignant findings). Women with BI-RADS 0 assessment (needs additional imaging evaluation) that are subsequently found to have negative (BI-RADS 1) or benign findings (BI-RADS 2), are NOT excluded.
At least one bi-dimensional measurable lesion with minimum measurement of > 15 mm in the longest diameter.
Patients must have bi-dimensionally measurable disease defined as at least one lesion that can be accurately measured in at least two planes in order to be eligible for this study
Patients must have bi-dimensionally measureable disease defined as at least one lesion that can be accurately measured in at least two planes
Subjects must have at least one bi-dimensionally measurable lesion; one of the measurements must be >= 1.5 cm in one dimension
Bi-lineage or bi-phenotypic leukemias
Patients must have measurable (>= 1.5 cm) or evaluable disease; baseline measurements and evaluations must be obtained within 21 days of registration to the study; abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging; measurable disease must have at least one objective measurable disease parameter; a clearly defined, bi-dimensionally measurable defect or mass measuring at least 1.5 cm in diameter on a CT scan will constitute measurable disease; proof of lymphoma in the liver is required by a confirmation biopsy; skin lesions can be used as measurable disease provided bi-dimensional measurements are possible
Participant has ? 1 site of bi-dimensionally measurable disease measured using contrast enhanced MRI.
Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (at least one objectively bi-dimensionally measurable (nodal) lesion (>2 cm in its largest dimension by CT scan).
At least one measurable GBM lesion that meets the following criteria:\r\n* Contrast enhancing and clearly defined, bi-dimensionally measurable margins, and\r\n* At least two perpendicular diameters measuring >= 10 mm and no diameters measuring >= 35 mm\r\n* (Note: MRI measurements will not include surgical cavity, cyst, or necrotic area)
Patients must have bi-dimensional measurable disease, as defined as radiographically apparent disease with the longest dimension of >= 1.5 cm
Non-WM must have at least one bi-dimensionally measurable lesion (that has not been previously irradiated) according to the Lugano Classification.
Patients affected by WM who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ? 2 x upper limit of normal (ULN) and positive immunofixation test.
Patients should have bi-dimensional measurable disease using the Cheson criteria (measureable disease by computed tomography [CT] scan defined as at least 1 lesion that measures >= 1.5 cm in single dimension)
Patients affected by WM who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ? 2 x upper limit of normal (ULN) and positive immunofixation test .
Patients must have measurable disease other than the injection site or biopsy site, i.e. greater than 1.5 cm bi-dimensionally on standard computed tomography imaging
Bi-dimensionally measurable disease (as per Revised Assessment in Neuro-Oncology [RANO] criteria)
Newly diagnosed MCL: Patients should in general have bi-dimensional measurable disease with\r\ntheir biggest tumor less than 10 cm; (bone marrow or gastrointestinal [GI] only involvement is acceptable)
Newly diagnosed MCL: Patients with bi-dimensional measurable disease with a tumor >= 10 cm
Patients should in general have bi-dimensional measurable disease using the Cheson criteria (measurable disease by computed tomography [CT] scan defined as at least 1 lesion that measures >= 1.5 cm in single dimension) (bone marrow or gastrointestinal [GI] only involvement is acceptable).
FOR TISSUE COLLECTION TO ESTABLISH PDX (PART 1): Patients must have bi-dimensional measurable disease as per Cheson criteria (bone marrow or gastrointestinal [GI] only involvement is acceptable).
Phase I (Cohorts T, and T2): Greater than or equal to (>/=) 1 bi-dimensionally measurable lesion on computed tomography (CT) scan
At least one bi-dimensionally measurable nodal lesion >1.5 cm in its longest diameter by computed tomography (CT) scan or MRI, as defined by the Lugano Classification
Must have at least one bi-dimensionally measurable lesion (greater than [>] 1.5 centimeters [cm] in its largest dimension by CT scan or Magnetic Resonance Imaging [MRI])
At least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by CT scan or magnetic resonance imaging [MRI])
At least one bi-dimensionally measurable lesion (greater than [>] 1.5 centimeters in its largest dimension by CT scan or magnetic resonance imaging)
Progression of bi-dimensionally measurable soft tissue (nodal metastasis) assessed within 1 month prior to registration by a CT scan or MRI of the abdomen and pelvis.
At least one bi-dimensionally measurable lesion on CT scan defined as more than (>) 1.5 centimeters (cm) in its longest dimension
At least one bi-dimensional measurable lesion
Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic imaging per immune-related response criteria (irRC).
Bi-dimensionally measurable disease (> 2.0 cm).
Patients with measurable disease must have at least one objective measurable disease parameter; a clearly defined, bi-dimensionally measurable defect or mass measuring at least 1.5 cm in diameter on the CT portion of a PET/CT or CT scan or magnetic resonance imaging (MRI) (if appropriate) will constitute measurable disease; proof of lymphoma in the liver is required by a confirmation biopsy; skin lesions can be used as measurable disease provided bi-dimensional measurements are possible
Patients must have bi-dimensional measurable disease (measureable disease by computed tomography [CT] scan defined as at least 1 lesion that measures >=1.5 cm in single dimension); patient with leukemia phase (peripheral blood involvement), non-measurable disease, gastrointestinal (GI) mantle cell lymphoma (MCL), or bone marrow (BM) MCL are also eligible; gastrointestinal or bone marrow or spleen only patients are allowable and will be analyzed separately
Patients affected by WM, who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment, must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ? 2 x upper limit of normal (ULN)and positive immunofixation test.
Patients must have bi-dimensional measurable disease (measurable disease by computed tomography [CT] scan defined as at least 1 lesion that measures >= 1.5 cm in single dimension); patient with leukemia phase (peripheral blood involvement), non-measurable disease, gastrointestinal (GI) MCL, or bone marrow (BM) MCL are also eligible
The primary and nodal involvement must have been defined bi- or uni-dimensional measurements measurable by RECIST
Must have at least one bi-dimensionally measurable lesion ?1.5 cm) documented by CT scan.
Patients must have bi-dimensional measurable disease (bone marrow only involvement is acceptable)
At least one bi-dimensionally measurable lesion (greater than [>] 2 cm in its largest dimension by computed tomography [CT] scan or magnetic resonance imaging [MRI])
All participants must have at least one bi-dimensionally measurable lesion (greater than [>]1.5 centimeters (cm) in its largest dimension by computed tomography [CT] scan)
Patients must have bi-dimensional measurable disease (bone marrow only involvement is acceptable)
Measurable disease is defined as at least one bi-dimensionally measurable non-lymph node lesion greater than or equal to (>/=) 1 centimeter (cm) on long access diameter on computed tomography (CT) or magnetic resonance imaging (MRI) scan or at least one bi-dimensionally measurable lymph node measuring >/=1.5 cm on short access diameter on CT or MRI scan
Presence of at least one lesion of bi-dimensionally measurable disease on baseline
Bi-dimensionally measurable disease within the bone
At least one bi-dimensionally measurable lesion on imaging scan defined as >1.5 centimeters (cm) in its longest dimension
All patients must have bi-dimensionally measurable disease with lesions at least 1.5 cm in one dimension all measurable disease must be assessed within 28 days of registration
At least one bi-dimensionally measurable lesion on imaging scan defined as >1.5 centimeters (cm) in its longest dimension
Measureable disease, defined as at least one bi-dimensionally measurable non-lymph node lesion greater than or equal to (>/=) 1 centimeter (cm) in long-axis diameter on spiral computed tomography (CT) scan or at least one bi-dimensionally measurable lymph node measuring >/= 1.5 cm in short-axis diameter on spiral CT scan
Prior treatment with BI 836826.
At least two bi-dimensionally measurable nodal lesions ? 1.5 centimeters (cm) in its longest diameter by imaging
Patients must have bi-dimensional measurable disease
Must have bi-dimensionally measurable disease
Patients must have measurable disease, documented by clinical, radiographic or histologic criteria; disease must be bi-dimensionally measurable by computed tomography (CT) or magnetic resonance imaging (MRI)
Patients must have a diagnostic quality computed tomography (CT) scan or magnetic resonance imaging (MRI), performed within 28 days prior to registration, which demonstrates measurable disease, as defined in RECIST v. 1.1; all disease must be assessed and documented on the S1609 Baseline Tumor Assessment Form
Patients must have measurable or non-measurable disease; patients must have a chest/abdominal/pelvis computed tomography (CT) scan (or positron emission tomography [PET]/CT of diagnostic quality, conventional or spiral) prior to registration; if the patient is unable to undergo CT with IV contrast due to allergy or renal insufficiency, a non-contrast CT may be performed; all scans needed for assessment of measurable disease must be performed within 28 days prior to registration; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to sub-study registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to sub-study registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration
Patients must also have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension; disease X-rays, scans or physical examinations used for tumor measurement must have been completed within 28 days prior to registration; if there is clinical suspicion for bone metastases at the time of enrollment (at the discretion of the investigator), bone scan should be performed at baseline (within 42 days prior to registration); all disease must be assessed and documented on the Baseline Tumor Assessment form
Patients must have measurable disease documented by CT or magnetic resonance imaging (MRI); the CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to step 1 registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to step 1 registration; all disease must be assessed and documented on the RECIST 1.1 and modified RECIST baseline tumor assessment form
All patients must have measurable disease documented by CT, MRI, or nonmeasurable disease documented by physical exam within 28 days prior to registration
Patients with measurable disease and/or non-measurable or no evidence of disease assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in this study.
Criteria 3 Measurable disease with at least 1 of the following assessed within 21 days prior to randomization:
Measurable disease on MRI performed within 14 days prior to registration.
Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to Step 2 re-registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to Step 2 re-registration; all disease must be assessed and documented on the baseline tumor assessment form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration
Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to re-registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to re-registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration
Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to step 2 re-registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to step 2 re-registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration
Patients must have measurable or non-measurable disease by both RECIST and modified RECIST criteria for pleural tumors as documented by computed tomography (CT) scan; examinations for assessment of measurable disease must have been completed within 28 days prior to registration; examinations for assessment of non-measurable disease must have been performed within 42 days prior to registration; all disease must be assessed and documented on the RECIST 1.1 and Modified RECIST Baseline Tumor Assessment Form
Patients may have measurable or non-measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality; laboratory parameters are not acceptable as the only evidence of disease; in order to qualify as measurable, measurable disease must be outside previous radiation field; all disease must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
DISEASE RELATED CRITERIA: Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI) within 28 days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality; non-measurable disease must be assessed within 42 days prior to registration; all known sites of disease must be assessed and documented on the baseline tumor assessment form (Response Evaluation Criteria in Solid Tumors [RECIST 1.1])
Patients must have measurable or non-measurable disease documented by CT, magnetic resonance imaging (MRI) or PET/CT; the CT from a combined PET/CT may be used to document only non-measurable disease unless the scan is of diagnostic quality; measurable disease must be assessed by CT within 28 days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
Patients may have measurable or non-measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to re-treatment registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to re-treatment registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to RE-TREATMENT registration
Patients must have measurable or non-measurable disease documented by computed tomography (CT) scan; measurable disease must be assessed within 28 days prior to registration; non-measurable disease must be assessed within 42 days prior to registration; the CT from a combined positron emission tomography (PET)/CT must not be used to document measurable disease unless it is of diagnostic quality; all disease must be assessed by RECIST and modified RECIST criteria
Measurable disease with at least 1 of the following assessed within the 21 days prior to randomization:
Patients must have measurable or non-measurable disease; all measurable lesions must be assessed (by physical examination, computed tomography [CT], or magnetic resonance imaging [MRI] scan) within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Patients must have measurable disease; all measurable lesions must be assessed (by physical examination, CT, or MRI scan) within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (RECIST 1.1)
Measurable disease assessed by one of the following ?21 days prior to registration:
Patients may have measurable or non-measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease; measurable disease must be assessed within 30 days prior to registration per response evaluation criteria in solid tumors (RECIST) version (v)1.1; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non- measurable disease must be assessed within 30 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
Patients must have measurable disease per RECIST documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within 28 days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form RECIST 1.1
Measurable disease, as defined by 1 or more of the following (assessed within 21 days prior to randomization):
Measurable disease, as defined by one or more of the following (assessed within 21 days prior to randomization):
Measurable disease (assessed within 28 days prior to day 1)
